fbpx Skip to main content

WEDNESDAY, Sept. 30, 2020 (HealthDay News) — Health care workers (HCWs) diagnosed with COVID-19 can have a prolonged recovery of viral RNA, which can delay return to work (RTW), according to research published online Aug. 26 in Infection Control & Hospital Epidemiology.

Erica S. Shenoy, M.D., Ph.D., from Massachusetts General Hospital in Boston, and colleagues evaluated average intervals until test-based clearance and the number of excess lost work days using test-based clearance as guidance for RTW for HCWs with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

The researchers found that between March 7 and April 22, 2020, 8,930 employees were tested and 11.7 percent were positive for SARS-CoV-2. Of those testing positive, 3.5 percent were hospitalized through the health care system within seven days of their positive test. A total of 590 HCWs had subsequent testing, with 72 percent having at least one negative nasopharyngeal (NP) swab. From first positive to first negative test, the mean and median number of days were 17.1 and 17 days, respectively (range, two days to 38 days). Six in 10 HCWs (61.9 percent) had a sequential second negative NP, with a mean and median number of days from first positive to second negative of 19.5 and 19 days, respectively (range, six days to 37 days). The estimated median time to clearance was 29 days. Using test-based clearance for RTW accounted for an additional 4,097 days of cumulative lost work time (mean 7.2 additional days of work lost per employee) versus using the time- plus symptom-based clearance method.

“Switching to time plus symptom-based clearance criteria will allow an earlier RTW for most workers and can aid in workforce preservation,” the authors write.

You May Also Like::  Physician's Briefing Weekly Coronavirus Roundup

Abstract/Full Text (subscription or payment may be required)

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More